Your browser doesn't support javascript.
loading
Advances in treatment for lipoid proteinosis (Urbach-Wiethe disease): a case report and systematic review.
Bueno-Molina, Rocío C; Hernández-Rodríguez, Juan-Carlos; Cabrera-Fuentes, Raquel; Cabrera-Pérez, Rocío; Conejo-Mir Sánchez, Julián; Pereyra-Rodríguez, José-Juan.
Afiliación
  • Bueno-Molina RC; Departments of Dermatology.
  • Hernández-Rodríguez JC; Departments of Dermatology.
  • Cabrera-Fuentes R; Departments of Dermatology.
  • Cabrera-Pérez R; Pathological Anatomy, Virgen del Rocio University Hospital, Seville, Spain.
  • Conejo-Mir Sánchez J; Departments of Dermatology.
  • Pereyra-Rodríguez JJ; Pathological Anatomy, Virgen del Rocio University Hospital, Seville, Spain.
Clin Exp Dermatol ; 49(6): 547-555, 2024 May 21.
Article en En | MEDLINE | ID: mdl-38308656
ABSTRACT

BACKGROUND:

Lipoid proteinosis (LP), also known as Urbach-Wiethe disease, is a rare autosomal recessive genodermatosis, caused by mutations in the ECM1 gene. This results in the deposition of periodic acid-Schiff (PAS)-positive, hyaline-like material on the skin, mucosae and internal organs.

OBJECTIVES:

To present a case report of LP and a systematic review to synthesize the scientific literature on the management of this uncommon and frequently missed diagnosis.

METHODS:

We present a case report of a 48-year-old man with LP who exhibited significant improvement after oral acitretin therapy. To address the lack of large case-control studies on LP treatment, we performed a systematic review of the literature following the PRISMA 2020 criteria. The search was conducted in PubMed, Web of Science, Cochrane and Scopus databases from inception until June 2023. To assess the methodological quality of case reports and case series, we used the Joanna Briggs Collaboration critical appraisal tool.

RESULTS:

We included 25 studies that met eligibility criteria. Data from 44 patients with a histopathologically confirmed diagnosis were analysed. Treatment ranged from systemic therapies (acitretin, etretinate, dimethyl sulfoxide, corticosteroids, penicillamine) to surgical or laser procedures. Regarding methodological quality, the main discrepancies arose in the reporting of participant characteristics and treatment interventions.

CONCLUSIONS:

Low-dose oral acitretin could have potential in managing LP, exhibiting fewer side-effects compared with other therapeutic agents. Further research is needed to establish more comprehensive and evidence-based treatment guidelines.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acitretina / Proteinosis Lipoidea de Urbach y Wiethe Tipo de estudio: Guideline / Observational_studies / Systematic_reviews Límite: Humans / Male / Middle aged Idioma: En Revista: Clin Exp Dermatol Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acitretina / Proteinosis Lipoidea de Urbach y Wiethe Tipo de estudio: Guideline / Observational_studies / Systematic_reviews Límite: Humans / Male / Middle aged Idioma: En Revista: Clin Exp Dermatol Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido